The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).

about

Conclusion and future perspectives on antifungal stewardship.Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

P2860

Q38791567-33C3BA71-C713-45C4-A6D2-65E12E2E6388 Q46324582-12AFD6CD-578B-4A52-BA65-3952AACB0DF4

P2860

The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).

Item

http://www.wikidata.org/entity/Q39189670

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The current treatment landscap ...... fusariosis and mucormycosis).

@en

The current treatment landscap ...... fusariosis and mucormycosis).

@nl

type

Item

label

The current treatment landscap ...... fusariosis and mucormycosis).

@en

The current treatment landscap ...... fusariosis and mucormycosis).

@nl

prefLabel

The current treatment landscap ...... fusariosis and mucormycosis).

@en

The current treatment landscap ...... fusariosis and mucormycosis).

@nl

P1476

The current treatment landscap ...... fusariosis and mucormycosis).

@en

P2093

Mario Fernández-Ruiz

http://www.w3.org/2001/XMLSchema#string

P2860

Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings

Diabetes and mucormycosis: a complex interplay

Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis

Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing

Population-based analysis of invasive fungal infections, France, 2001-2010.

Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda

Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

P304

ii31-ii36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKW394

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Lortholary

John R Perfect

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27880667

http://www.w3.org/2001/XMLSchema#string

P921

cryptococcosis

The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).

about

P2860

P2860

The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921